Eisai Co., Ltd. (ESALF)
| Market Cap | 8.84B +15.4% |
| Revenue (ttm) | 5.15B +2.1% |
| Net Income | 272.70M -27.3% |
| EPS | 0.97 -26.6% |
| Shares Out | n/a |
| PE Ratio | 32.42 |
| Forward PE | n/a |
| Dividend | 1.06 (3.96%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 200 |
| Average Volume | 355 |
| Open | 26.76 |
| Previous Close | 26.76 |
| Day's Range | 26.76 - 26.76 |
| 52-Week Range | 22.51 - 35.83 |
| Beta | -0.28 |
| RSI | 42.38 |
| Earnings Date | Feb 9, 2026 |
About Eisai
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals. It also offers prescription medicines. In addition, the company focuses on neurology and oncology and therapeutic areas. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan. [Read more]
Full Company ProfileFinancial Performance
In fiscal year 2025, Eisai's revenue was 789.40 billion, an increase of 6.42% compared to the previous year's 741.75 billion. Earnings were 46.43 billion, an increase of 9.49%.
Financial numbers in JPY Financial StatementsNews
Biogen Hits 52-Week High, Alzheimer's Drug Sales Jump
Biogen Inc. (NASDAQ: BIIB) on Friday reported better-than-expected fourth-quarter earnings, with adjusted EPS of $1.99, beating the consensus of $1.59 . The Alzheimer's drug maker reported revenues o...
Fosun Pharma’s US$1.55 billion Eisai deal signals shift to long-term partnerships
A unit of Fosun Pharma has struck a US$1.55 billion deal to license its home-grown cancer drug to Japan’s Eisai, adding to a wave of out-licensing agreements that are channelling billions of dollars i...
Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
TOKYO and SHANGHAI, Feb. 5, 2026 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Shanghai Henlius Biotech, Inc. (Headquarters: Shanghai, China, CEO: Jason Zhu, "He...
Eisai strikes Japan licensing deal with Shanghai Henlius Biotech
Japan's Eisai will licence Shanghai Henlius Biotech's lung cancer drug Hansizhuang, paying $75 million upfront and up to $313.34 million more if milestones are met, the Chinese drugmaker said on Thurs...
FDA Accepts To Priority Review Eisai And Biogen's LEQEMBI SBLA For Early Alzheimer's Disease
(RTTNews) - Eisai Co., Ltd, (4523.T, ESALY.PK, ESALF.PK), a Japanese commercial-stage biotechnology firm and Biogen Inc. (BIIB) said the U.S. Food and Drug Administration (FDA) has accepted for priori...
FDA Grants Priority Review To Eisai And Biogen's SBLA For LEQEMBI Subcutaneous Autoinjector
(RTTNews) - Eisai Co., Ltd. (ESALY, ESALF, 4523.T) and Biogen Inc. (BIIB) announced that the U.S. Food and Drug Administration has accepted for review Eisai's Supplemental Biologics License Applicatio...
FDA Accepts LEQEMBI® IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive, relentless disease FDA acti...
FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive, relentless disease FDA acti...
LARGE CAP INTERNATIONAL PORTFOLIO Buys Shares of Eisai Co Ltd (4523)
LARGE CAP INTERNATIONAL PORTFOLIO Buys Shares of Eisai Co Ltd (4523)
Nuvation Bio (NUVB) Expands Global Reach with Eisai Collaboration
Nuvation Bio (NUVB) Expands Global Reach with Eisai Collaboration
China’s new drug insurance: lifeline for patients or squeeze on big pharmaceutical firms?
Mainland China’s 17 million Alzheimer’s patients can, for the first time, pay less out of pocket for a costly drug touted as “historic” and “the beginning of the end” for the memory-robbing disease af...
Eisai Co., Ltd. (ESAIY) Discusses Value Creation Initiatives, ESG, and Dementia Area Contributions Transcript
Eisai Co., Ltd. (ESAIY) Discusses Value Creation Initiatives, ESG, and Dementia Area Contributions December 9, 2025 1:30 AM ESTCompany ParticipantsAya...
Eisai Co., Ltd. (ESAIY) Discusses Value Creation Initiatives, ESG, and Dementia Area Contributions - Slideshow
Eisai And Biogen Report Long-Term Benefits Of LEQEMBI In Early Alzheimer's Disease
(RTTNews) - Eisai Co., Ltd. and Biogen Inc. announced new findings on the continued and expanding benefit of LEQEMBI (lecanemab-irmb) maintenance treatment in early Alzheimer's disease at the 18th Cli...
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025
TOKYO and CAMBRIDGE, Mass., Dec. 3, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusett...
Eisai : Etalanetug Demonstrates Reduction Of EMTBR-tau243 In Phase Ib/II Alzheimer's Study
(RTTNews) - Eisai Co., Ltd. announced new data on its anti-tau antibody etalanetug at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference. Etalanetug is designed to bind to the microtubu...
Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
Etalanetug demonstrated reduction of eMTBR-tau243, a novel CSF and plasma biomarker that specifically reflects tau tangle pathology, in Phase I b /II study TOKYO , Dec. 1, 2025 /PRNewswire/ -- Eisai C...
Biogen, Eisai File In Japan To Make Leqembi A Weekly At-Home Alzheimer's Shot
Biogen Inc. ‘s (NASDAQ: BIIB) partner Eisai Co., Ltd , on Friday filed a new drug application for Leqembi (lecanemab) seeking approval for a subcutaneous formulation (SC-AI) as a new route of adminis...
Eisai Announces Filing Of New Drug Application For Leqembi In Japan
(RTTNews) - BioArctic AB's (BIOA-B.ST) partner Eisai (4523.T) announced that they have filed a new drug application for Leqembi or lecanemab for a subcutaneous formulation as a new route of administra...
Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
TOKYO and CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ: BIIB , Corporate headquarters: Cambridge, Massac...
Eisai to Present Data on Lecanemab Continued Treatment, Subcutaneous Initiation Dosing, and Real-World Experience at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference
Latest findings from Eisai's robust Alzheimer's disease (AD) pipeline explore long-term treatment with lecanemab and estimated time savings over 10 years, safety and potential benefits of subcutaneous...
Q2 2026 Eisai Co Ltd Earnings Presentation Transcript
Q2 2026 Eisai Co Ltd Earnings Presentation Transcript